Roswell Park Cancer Institute began working collaboratively with scientists from the Center for Molecular Immunology, or Centro de Inmunologia Molecular (CIM), in Havana, Cuba, in 2011.
This research partnership with the CIM, highlighted in a Department of Commerce fact sheet, took an important step forward with our participation in the trade mission to Cuba led by New York Gov. Andrew Cuomo in April 2015.
In late 2016, we received permission from the U.S. Food and Drug Administration (FDA) to conduct an early-stage clinical trial with CIMAvax-EGF, a therapeutic lung cancer vaccine developed by the CIM. That clinical trial in patients with advanced lung cancer began in January 2017 and is now underway.
- Roswell Park is the only U.S. center partnering with the CIM to develop CIMAvax, and holds a license from the U.S. Office of Foreign Assets Control (OFAC) that permits preclinical and clinical research using CIMAvax-EGF.
- CIMAvax has already been used to treat about 5,000 patients worldwide, and is approved for use in Bosnia and Herzegovina, Colombia, Cuba, Paraguay and Peru. See the most recent published vaccine research.
- In addition to showing promise as a therapeutic vaccine for lung cancer, CIMAvax may also prove effective in treating colon, head and neck, prostate, breast and pancreatic cancers — and potentially could be used to prevent cancer.
- The CIMAvax study is now open. Those who complete our online eligibility form and are found to be eligible to participate will be contacted. To see what other clinical studies are currently open at Roswell Park, please view our clinical trials or contact our ASK-RPCI team at 1-877-ASK-RPCI (1-877-275-7724) or email@example.com.